Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...
According to Texas-based energy consulting and services firm Enverus, interconnection queues remain one of the most significant barriers to bringing new generation capacity online. The company’s 2026 ...
Abstract: Glaucoma, an irreversible neurodegenerative disorder, can lead to vision loss and blindness. Visual field (VF) tests are crucial for quantifying functional damage in glaucoma, but the tests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results